Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn, a manufacturer and marketer of diagnostic and therapeutic pharmaceuticals, has announced that the FDA has granted approval for the company's abbreviated new drug application for Adenosine injection USP, 3 mg/mL.
Subscribe to our email newsletter
Adenosine injection is indicated for supraventricular tachycardia in cardiac patients.
Arthur Przybyl, Akorn’s president and CEO, said: “We are pleased to announce the abbreviated new drug application (ANDA) approval for Adenosine. This product is manufactured at our Decatur, Illinois manufacturing facility and represents another important addition to our injectable product line. We expect to launch Adenosine in 2009.”